SESSION TITLE: Treatment of IPF
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Monday, October 24, 2016 at 07:30 AM - 08:30 AM
PURPOSE: A pooled analysis of data from the Phase III CAPACITY trials demonstrated that the effect of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) was independent of baseline percent predicted forced vital capacity (FVC). The objective of this analysis was to further examine the course of FVC during long-term treatment with pirfenidone in patients stratified by intervals of baseline percent predicted FVC in RECAP, a long-term extension study of the CAPACITY trials.